In Bevacizumab-Treated Colorectal Cancer, Certain Gene Variations Linked With Outcomes

Share this content:
Variations in genes regulating tumor-associated macrophages-related functions associated with outcomes in metastatic colorectal cancer.
Variations in genes regulating tumor-associated macrophages-related functions associated with outcomes in metastatic colorectal cancer.

Variations in genes regulating tumor-associated macrophages (TAMs)-related functions are significantly associated with clinical outcomes in patients with metastatic colorectal cancer (mCRC) treated with bevacizumab-containing chemotherapy, a new study published online ahead of print in the journal Annals of Oncology has shown.1

For the study, researchers analyzed genomic DNA from tumor samples of patients receiving bevacizumab plus FOLFIRI (fluorouracil, leucovorin, irinotecan) as first-line treatment. Researchers tested 12 functional single-nucleotide polymorphisms in the genes CCL2, CCR2, HRG, PIGF, NFKB1, TBK1, CCL18, and IRF3 for associations with clinical outcomes in 228 participants of the TRIBE trial. Results were then validated in 248 KRAS wild-type participants of the FIRE3 trial.

Results showed that TBK1 rs7486100 was significantly associated with overall survival in KRAS wild-type patients in univariate analysis and had a strong trend toward significance in multivariable analysis.

In addition, researchers observed an association between the T allele and progression-free survival in bevacizumab-treated patients but not cetuximab-treated patients.

RELATED: FDA Approves Trifluride Plus Tipiracil for Advanced Colorectal Cancer

The study also demonstrated associations between CCL2 rs4586, CCL18 rs14304, and IRF3 rs2304205 and progression-free survival in KRAS mutant patients.

“These results also suggest that some TAM-related gene variations may predict outcomes of bevacizumab treatment in KRAS status-dependent manner,” the authors concluded.

Reference

  1. Sumakawa Y, Stintzing S, Cao S, et al. Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials [published online ahead of print September 28, 2015]. Ann Oncol. doi: 10.1093/annonc/mdv474.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs